|
37个自闭孩子,3-11岁,一组接受DMG,一组接受安慰剂。4周。
结果: 两组孩子都有一定的提高(行为标准)。两组的提高没有统计区别。孩子对DMG的反映不均一。一些吃了DMG的孩子似乎有好的变化,更少的一些孩子吃了DMG有坏变化,但总的来说和安慰剂组没有量上的(quantitative)差别。
没有原文(长篇的),所以不知道这里的行为测的是什么。我看有的报道有的孩子吃了DMG可以引起的多动或睡眠差的问题。
J Child Neurol. 2001 Mar;16(3):169-73. Links
Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder.
Kern JK, Miller VS, Cauller PL, Kendall PR, Mehta PJ, Dodd M.
Department of Human Development, University of Texas at Dallas, USA. jkern1@mednet.swmed.edu
N,N-dimethylglycine, a dietary supplement, has been reported to be beneficial in children with autism and pervasive developmental disorder. We examined the effectiveness of dimethylglycine in children with autism and pervasive developmental disorder in a double-blind, placebo-controlled study. Thirty-seven children between 3 and 11 years of age with a diagnosis of autism and/or pervasive developmental disorder were gender and age matched and randomly assigned to receive either placebo or dimethylglycine for 4 weeks. All children were assessed before and after treatment on two behavioral measures, the Vineland Maladaptive Behavior Domain and the Aberrant Behavior Checklist. Standardized neurologic examinations before and after treatment on 33 children showed no change. An overall improvement on all behavioral measures was observed for both the placebo and the dimethylglycine groups. However, the improvement among the children who received dimethylglycine was not statistically different from the improvement observed among the children who received the placebo. The children who participated in this study were a heterogeneous group, and their apparent responses to the dimethylglycine varied. Some children appeared to respond positively to the dimethylglycine, and there was a smaller proportion of negative changes in the dimethylglycine group, but the quantitative changes in the dimethylglycine behavioral assessments were not significantly different from what was observed among children who received placebo.
|
|